Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism

被引:0
|
作者
Shani Journo
Anat Klein Goldberg
Ethan S Sokol
Lotem Zinger
Metsada Pasmanik-Chor
Boris Sarvin
Dor Simkin
Sivan Fuchs
Tomer Shlomi
Ido Wolf
Tami Rubinek
机构
[1] Tel Aviv Sourasky Medical Center,Institute of Oncology
[2] Tel Aviv University,Sackler Faculty of Medicine
[3] Foundation Medicine,Bioinformatics Unit, Faculty of Life Sciences
[4] Inc.,undefined
[5] Tel Aviv University,undefined
[6] Faculty of Computer Science at Technion; and Faculty of Biology at Technion,undefined
来源
Oncogene | 2022年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Metastases are often the direct cause of death from pancreatic ductal adenocarcinoma (PDAC). The role of genomic alterations (GA) in mediating tropism and metastasis formation by PDAC cells is currently unknown. We aimed to identify GAs predisposing colonization of PDAC cells to the liver and decipher mechanisms enabling this process. In order to reveal specific genes, we studied the frequency of GA in 8,880 local and 7,983 metastatic PDAC samples. We observed differential pattern of GA in the local tumor and specific metastatic sites, with liver metastases characterized by deletion of CDKN2A/B (encoding p16/p15, respectively). The role of CDKN2A/B in promoting liver metastasis was evidenced by enhanced tumorigenic phenotype of p15/p16-deleted PDAC cells when exposed to hepatocytes conditioned media. The liver is characterized by high-ammonia low-glutamine environment and transcriptomic assays indicated unique adaptation of PDAC cells to these conditions, including regulation of genes leading to reduced glutaminolysis, like overexpression of GLUL and reduction in GLS2. Furthermore, metabolic assays indicated an increase in glutamate derived from [U-13C]-glucose in p15/p16-deleted cells. Importantly, these cells thrived under high ammonia condition. These data suggest a unique role for genomic alterations in mediating tropism of PDAC. Among these alterations, p15/16 deletion was identified as a promoter of liver metastases. Further studies indicated a unique role for p15/16 in regulating glutaminolysis. These findings reveal vulnerabilities in PDAC cells, which may pave the way for the development of novel therapeutic strategies aiming at the prevention of liver metastases formation.
引用
收藏
页码:1468 / 1481
页数:13
相关论文
共 40 条
  • [1] Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism
    Journo, Shani
    Goldberg, Anat Klein
    Sokol, Ethan S.
    Zinger, Lotem
    Pasmanik-Chor, Metsada
    Sarvin, Boris
    Simkin, Dor
    Fuchs, Sivan
    Shlomi, Tomer
    Wolf, Ido
    Rubinek, Tami
    ONCOGENE, 2022, 41 (10) : 1468 - 1481
  • [2] Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
    Voutsadakis, Ioannis A.
    Digklia, Antonia
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (01)
  • [3] Molecular genetic analysis of oligodendroglial tumors for alterations of the CDKN2A and CDKN2B tumor suppressor genes
    Wolter, M
    Reifenberger, J
    Ichimura, K
    Schmidt, EE
    Collins, VP
    Reifenberger, G
    BRAIN PATHOLOGY, 2000, 10 (04) : 570 - 571
  • [4] Pan-cancer genomic variation characteristics of CDKN2A/CDKN2B/CCND1 in Chinese patients.
    Yu, Songfeng
    Li, Qiyong
    Dai, Lei
    Zhao, Peng
    Zhuang, Li
    Qian, Yigang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Alterations of the cyclin-dependent kinase inhibitor genes CDKN2A, CDKN2B and CDKN2C in atypical and anaplastic meningiomas
    Boström, J
    Meyer-Puttlitz, B
    Blaschke, B
    Wolter, M
    Weber, RG
    Lichter, P
    Collins, VP
    Reifenberger, G
    BRAIN PATHOLOGY, 2000, 10 (04) : 742 - 742
  • [6] CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A
    Tu, Q.
    Hao, J.
    Zhou, X.
    Yan, L.
    Dai, H.
    Sun, B.
    Yang, D.
    An, S.
    Lv, L.
    Jiao, B.
    Chen, C.
    Lai, R.
    Shi, P.
    Zhao, X.
    ONCOGENE, 2018, 37 (01) : 128 - 138
  • [7] CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A
    Q Tu
    J Hao
    X Zhou
    L Yan
    H Dai
    B Sun
    D Yang
    S An
    L Lv
    B Jiao
    C Chen
    R Lai
    P Shi
    X Zhao
    Oncogene, 2018, 37 : 128 - 138
  • [8] Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic events in adult mice
    Jia, Xintong
    Sun, Bin
    Tu, Qiu
    Qi, Huaxin
    Li, Lin
    Liu, Xiuyun
    Yan, Lanzhen
    Dai, Hongjuan
    Kong, Qingpeng
    Tang, Chengwei
    Zhao, Xudong
    PANCREATOLOGY, 2021, 21 (02) : 418 - 427
  • [9] CDKN2A or CDKN2B homozygous deletion with high-immune infiltration as a favorable prognostic factor for lung adenocarcinoma.
    Tan, Benxu
    Chen, Yonghong
    Xia, Lei
    Yu, Xian
    Huang, Yusheng
    Zhang, Ni
    Peng, Yuan
    Song, Mengmeng
    Ji, Liyan
    Li, Pansong
    Xia, Xuefeng
    Yang, Zhenzhou
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Impact of CDKN2A/b status in pancreatic cancer (PC)
    Annunzio, Kaitlin
    Griffiths, Claire
    Arapi, Igli
    Lasowski, Matthew
    Singavi, Arun K.
    Dua, Kulwinder
    Khan, Abdul H.
    Ritch, Paul S.
    Kamgar, Mandana
    Thomas, James P.
    Hall, William Adrian
    Erickson, Beth
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Urrutia, Raul
    Szabo, Aniko
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)